Related Experiment Video
Updated: Nov 13, 2025
09:32
Network Analysis of Foramen Ovale Electrode Recordings in Drug-resistant Temporal Lobe Epilepsy Patients
Published on: December 18, 2016
12.7K
The Kappa Opioid Receptor System in Temporal Lobe Epilepsy
Luca Zangrandi1,2,3,4, Christoph Schwarzer5
1Institute of Virology, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Handbook of Experimental Pharmacology
|March 13, 2021
Summary
Dynorphins and the kappa opioid receptor (KOR) system show promise for treating temporal lobe epilepsy (TLE). Modulating this system may offer new anticonvulsant therapies for drug-resistant epilepsy.
Area of Science:
- Neuroscience
- Epileptology
- Pharmacology
Background:
- Temporal lobe epilepsy (TLE) is a severe focal epilepsy often leading to cognitive deficits and emotional blunting.
- Drug-resistant epilepsy and limited surgical options highlight the need for novel therapeutic strategies.
- Neuropeptides, including dynorphins (Dyns) and their kappa opioid receptor (KOR) system, are potential candidates for TLE treatment.
Purpose of the Study:
- To investigate the functional role of the dynorphin/KOR system in the hippocampus concerning temporal lobe epilepsy.
- To explore the therapeutic potential of modulating the dynorphin/KOR system for seizure control.
Main Methods:
- Analysis of genetic polymorphisms in the prepro-dynorphin (pDyn) gene and their association with epilepsy risk.
- Examination of KOR agonist effects on neuronal excitability, including presynaptic neurotransmitter release and postsynaptic hyperpolarization in glutamatergic neurons.
- Review of emerging therapeutic approaches like biased agonism and gene therapy targeting the KOR signaling cascade.
Main Results:
- Genetic variations linked to lower dynorphin levels increase epilepsy risk, suggesting a modulatory role for Dyns and KOR in neuronal excitability.
- KOR agonists demonstrate anticonvulsant effects by inhibiting presynaptic neurotransmitter release and causing postsynaptic hyperpolarization.
- Preclinical data indicate that targeting the KOR system can effectively control seizures.
Conclusions:
- The dynorphin/KOR system plays a significant role in modulating neuronal excitability and has anticonvulsant properties relevant to TLE.
- Novel therapeutic strategies targeting the KOR signaling cascade, such as biased agonism and gene therapy, offer promising avenues for seizure control.
- Minimizing potential adverse effects through functional selectivity or localized treatment could enhance the clinical utility of KOR-based therapies for TLE.
Related Concept Videos
01:22Opioid Receptors: Overview
3.0K
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
3.0K
01:25Analgesia and Pain Management
1.1K
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
1.1K
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
913
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
913
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
594
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
594
01:14Antiepileptic Drugs: Glutamate Antagonists
667
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
667